OncoLize (Maastricht-NL, 2017) offers the next step in injectable drug depots for better tumor treatment.

The company was founded by Mike de Leeuw (CEO), who previously founded InGell Labs (2010), Branching Tree (2008) and DSM BioMedical (2005).

Mike is joined by dr. Leo de Leede (CTO), a long-time biopharmaceutical expert using polymer-enabled drug delivery in a.o. Organon/MSD – Yamanuchi/Astellas – OctoPlus/Dr.Reddy – Branching Tree/ InGell Labs.

In the coming months we will announce a new and highly experienced  member joining our management team.

We recently switched to the OCL-platform, which is faster to formulate, easier to use in the clinic and far less costly to scale-up and approve (compared to our previous platform).

We have dedicated ourselves to develop products that deal with the urgent unmet needs for the ‘rare and deadly tumor diseases’.

Why?

  • Because we have seen too much suffering within our families, friends and colleagues.
  • Because little progress has been made for aggressive Pancreatic-,  Lung-, Liver-, Brain-tumors and various other less frequent occurring  solid tumors.
  • Because most new developments for these diseases come out very expensive, marginally effective if at all, and certainly not accessible for all.

Over the past ten years we have shown the versatility and robustness of the InGell-technology.

We believe that everybody should have access to the best possible care for these aggressive tumor diseases.

We are certain that this can be done by localizing generic drugs and novel drugs alike, with much better effect, far less side-effects, and at much lower costs to the national healthcare systems.